DOCSLIB.ORG

Functional Dyspepsia: a Review of the Symptoms, Evaluation, and Treatment Options

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Functional Dyspepsia: a Review of the Symptoms, Evaluation, and Treatment Options Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options Kimberly N. Harer, MD, ScM, and William L. Hasler, MD Dr Harer is a clinical lecturer and Dr Abstract: The community prevalence of dyspepsia ranges from Hasler is a professor in the Division of 20% to 40%, and dyspepsia accounts for 3% to 5% of primary care Gastroenterology in the University of visits. Dyspepsia symptoms include epigastric pain, epigastric burn- Michigan Health System in Ann Arbor, ing, postprandial fullness, early satiety, epigastric bloating, nausea, Michigan. and belching. Functional dyspepsia is diagnosed when an organic etiology for the symptoms is not identified. Diagnostic symptom- Address correspondence to: based criteria are defined by Rome IV. Functional dyspepsia is Dr William L. Hasler further subclassified into postprandial distress syndrome and University of Michigan Health System epigastric pain syndrome based on the predominance of post- 3912 Taubman Center, SPC 5362 prandial bloating and fullness vs epigastric pain. Evaluation of Ann Arbor, MI 48109 Tel: 734-936-4780 functional dyspepsia is driven by patient age and the presence of Fax: 734-936-7392 red-flag symptoms, such as patients over age 60 years or those with E-mail: [email protected] anemia undergoing evaluation with esophagogastroduodenoscopy. Helicobacter pylori infection should be excluded in all patients. Treatment options include proton pump inhibitors, neuromodu- lators, and prokinetics; however, the evidence supporting these therapies is weak, and the response rate is less than robust. he diagnosis and treatment of functional dyspepsia is often clinically challenging due to factors such as the heterogene- ity of upper gastrointestinal symptoms and the generalized Tpoor response to currently available treatment options. This article defines functional dyspepsia, discusses known and proposed patho- physiologic mechanisms, and outlines a recommended approach to the evaluation and treatment of the disorder. Definition and Clinical Presentation Dyspepsia symptoms include a constellation of upper gastrointesti- Keywords nal complaints, such as belching, postprandial fullness, early satiety, Epigastric pain, epigastric burning, early satiety, epigastric pain, and epigastric burning. Functional dyspepsia is diag- postprandial fullness, nausea, Helicobacter pylori, nosed when an organic etiology for the symptoms is not identified. peptic ulcer disease The disorder is defined by Rome IV criteria and subclassified into 66 Gastroenterology & Hepatology Volume 16, Issue 2 February 2020 FUNCTIONAL DYSPEPSIA Rome IV Criteria for Functional Dyspepsia • Presence of ≥1 symptom(s) of postprandial fullness, early satiety, epigastric pain, or epigastric burning • No evidence of structural disease that could explain the symptoms PDS EPS Postprandial fullness or early satiety Epigastric pain and/or burning ≥1 day(s)/ ≥3 days/week for the past 3 months and week for the past 3 months and onset onset ≥6 months before diagnosis ≥6 months before diagnosis PDS (38%) Overlap EPS (27%) PDS/EPS (35%) Symptoms Symptoms • Early satiety • Epigastric pain • Bloating • Epigastric burning • Nausea • Vomiting/retching • Decreased appetite Figure 1. Rome IV criteria for functional dyspepsia and its subclassifications. EPS, epigastric pain syndrome; PDS, postprandial distress syndrome. postprandial distress syndrome and epigastric pain syn- the inherent heterogeneity in symptoms as well as the sig- drome (Figure 1).1 Of patients with functional dyspepsia, nificant overlap in symptoms with other disorders, such as approximately 38% are classified with postprandial dis- gastroparesis, irritable bowel syndrome, and gastroesoph- tress syndrome, 27% are classified with epigastric pain ageal reflux disease. One study demonstrated that more syndrome, and 35% meet criteria for both.2 Dyspepsia than 50% of patients with functional dyspepsia with a patients often report a range of upper gastrointestinal normal pH study reported heartburn and regurgitation.4 symptoms,3 and this complex presentation is further In a study published by the National Institutes of Health complicated by the fact that patients use terms such as Gastroparesis Clinical Research Consortium, patients heartburn or indigestion to describe epigastric pain or with functional dyspepsia and idiopathic gastroparesis burning. Despite the Rome IV definition, diagnosis of were essentially clinically indistinguishable. Other studies functional dyspepsia often remains challenging due to have demonstrated that more than 25% of patients who Gastroenterology & Hepatology Volume 16, Issue 2 February 2020 67 HARER AND HASLER were diagnosed with functional dyspepsia had delayed approximately 40% have impaired gastric accommoda- gastric emptying,5 and 86% of patients with idiopathic tion.15 Research has also demonstrated impaired gastric gastroparesis met functional dyspepsia symptom criteria.6 emptying in patients with functional dyspepsia5; however, There is growing support for the thought that functional there is significant debate regarding whether functional dyspepsia and gastroparesis share pathophysiologic dyspepsia and gastroparesis are separate entities or if mechanisms and represent a spectrum of disorders driven they are part of a spectrum of gastric neuromuscular by duodenogastric neuromuscular dysfunction. Thus, it dysfunction disorders. This debate is largely driven by is crucial to complete a thorough history and physical evidence showing that patients with symptoms suggestive examination of the patient when working to identify the of gastroparesis (eg, early satiety, nausea, vomiting, and most likely etiology of the patient’s symptoms. For exam- postprandial fullness) in the setting of a normal gastric ple, predominant nausea and vomiting symptoms point emptying study are clinically indistinguishable from toward gastroparesis, and predominant postprandial right patients with the same symptoms and impaired gastric upper quadrant pain places a pancreaticobiliary etiology emptying.16 Impaired gastric accommodation has also higher on the differential diagnosis. been associated with increased transient lower esophageal sphincter relaxations, and the increased occurrence of Epidemiology of Dyspepsia these relaxations has been proposed as an explanation of the overlap between dyspepsia and gastroesophageal The community prevalence of dyspepsia is typically reflux disease symptoms within this patient population.17 quoted in the range of 20% to 40%, and the disorder accounts for 3% to 5% of primary care visits.7-12 Of Duodenal Acid Exposure, Dysmotility, and patients with investigated dyspepsia, approximately 70% Inflammation have negative endoscopic studies and approximately There is preliminary evidence concerning the presence 50% to 60% are subsequently classified as functional of increased postprandial duodenal acid exposure in dyspepsia.12,13 Admittedly, estimating the prevalence of functional dyspepsia patients with prominent nausea functional dyspepsia is challenging due to variable diag- symptoms.18 In addition, duodenal motility and bolus nostic criteria used in prevalence studies, the overlap in clearance impairment have been induced by instilling acid symptoms with other disorders, and inconsistent inter- into the duodenum, raising concern that duodenal acid– pretation of dyspepsia symptoms. Risk factors include driven pathology may contribute to dyspepsia symptoms female sex, increasing age, Helicobacter pylori infection, in a subset of patients. high socioeconomic status, smoking, and nonsteroidal There is growing evidence regarding the role of anti-inflammatory drug use. duodenal inflammation and duodenal eosinophilia in functional dyspepsia. Duodenal inflammation, and in Etiology of Functional Dyspepsia particular duodenal eosinophilia, has been seen in up to 40% of patients with functional dyspepsia.19-21 A mean The etiology of dyspepsia has been poorly defined; how- eosinophil count of 49 eosinophils per high-power field ever, numerous pathophysiologic mechanisms, most of was associated with a diagnosis of functional dyspep- which are directed at gastroduodenal pathways, have sia in one study19; however, data are lacking regarding been proposed to explain the disorder. Many mecha- normative values. The cause of duodenal eosinophilia is nisms are currently being investigated as potential causes unknown, but increased duodenal permeability, mast cell of functional dyspepsia symptoms. Given the number of disorders, and smoking are proposed to be contributing potentially unidentified etiologies for dyspepsia symp- factors. toms and the association of the word functional with The phenomenon of postinfectious irritable bowel a lack of an organic cause for symptoms, we cautiously syndrome due to bowel inflammation has been expanded use the term functional dyspepsia to describe dyspepsia to include postinfectious dyspepsia as a potential cause symptoms without an identified organic etiology. of functional dyspepsia.22 A systematic review and meta- analysis of 19 studies demonstrated a mean prevalence Gastric Neuromuscular Dysfunction of functional dyspepsia after acute gastroenteritis at Gastric neuromuscular dysfunction, including delayed approximately 10%, with an odds ratio for development gastric emptying, impaired gastric fundus relaxation with of postinfectious functional dyspepsia of 2.54 (95% CI, blunting of postprandial accommodation, and altered gas- 1.76-3.65).22 Norovirus is the most common cause of tric mechanosensitivity,
Load more

Recommended publications
  • Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal
    testinal & in D o i tr g s e Journal of Gastrointestinal & a s t G i v f e o Narayanan et al., J Gastrointest Dig Syst 2018, 8:1 S l y a s n r ISSN: 2161-069Xt Digestive System DOI: 10.4172/2161-069X.1000553 e u m o J Research Article Open Access Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal- related Symptoms of Functional Dyspepsia Varsha Narayanan*, Amit Bhargava and Shailesh Pallewar 1Department of Medical Services and Research, Lupin Ltd., India *Corresponding author: Narayanan V, Department of Medical Services and Research, Lupin Ltd., Mumbai, India, Tel: +912266402222; E-mail: [email protected] Received date: February 09, 2018; Accepted date: February 21, 2018; Published date: February 27, 2018 Copyright: © 2018 Narayanan V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: Functional Dyspepsia (FD) is a highly prevalent clinical condition that imposes negative economic burden on health-care system as well as greatly impairs quality of life. Treatment of non-specific and bothersome meal-related FD symptoms like post-prandial fullness, upper abdominal bloating and early satiety, is a therapeutic challenge for the clinicians as poorly-defined and ill-understood pathogenesis has hampered efforts to develop effective treatments. Acotiamide is first-in-class drug that exerts its gastro-kinetic effect by enhancing acetylcholine release. Though evidence of its efficacy and tolerance are available through randomized clinical trials, real world data from its regular in-clinic use is lacking.
    [Show full text]
  • PN0496-Acotiamide.Pdf
    Acotiamide hydrochloride hydrate (Acofide®) 盐酸阿考替胺 Z-338 in Zeria; YM-443 in Astellas Tablet, oral, EQ 100 mg acotiamide Acotiamide is a peripheral acetylcholinesterase inhibitor, indicated for the treatment of functional dyspepsia (FD), which was first-in-class drug to treat FD in the world and approved in 2013 by Japan PMDA. It was originally discovered by Zeria, and co-developed with Astellas. The drug is co-marketing in Japan with a single brand name. The human recommended starting dose is 100 mg at a time, and 3 times a day before meals. Worldwide Key Approvals Global Sales ($Million) Key Substance Patent Expiration 2016-May (US5981557A) 2016-May (EP0870765B1) 2013-Mar (JP) Not available 2021-May (JP3181919B2) 2016-May (CN1063442C) Mechanism of Action Acotiamide hydrochloride hydrate is an acetylcholinesterase (AChE) inhibitor and enhanced the acetylcholine (ACh)-induced contraction and motility of the gastric antrum and the gastric body. Target Binding Selectivity In vitro Efficacy In vivo Efficacy Mixed pattern: Ki1= 0.61 µM Effect dose of contraction in gastric sample: Significantly improved the gastrointestinal motility: Ki2= 2.7 µM ACh-induced: at 1 µM In normal and gastric hypomotility dogs: at 10 mg/kg. Inhibition: IC50= 3 µM Electrical-induced: at 0.3 µM In gastric hypomotility rats: at 100 mg/kg. Pharmacokinetics Parameters Rats Dogs Healthy Humans 3 10 3 10 50 mg 100 mg 200 mg 400 mg 800 mg Dose (mg/kg) (i.v.) (p.o.) (i.v.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) Tmax (hr) - 0.08 - 0.5 2.75 2.42 2.08 2.25 2.13 Cmax
    [Show full text]
  • Childhood Functional Gastrointestinal Disorders: Child/Adolescent
    Gastroenterology 2016;150:1456–1468 Childhood Functional Gastrointestinal Disorders: Child/ Adolescent Jeffrey S. Hyams,1,* Carlo Di Lorenzo,2,* Miguel Saps,2 Robert J. Shulman,3 Annamaria Staiano,4 and Miranda van Tilburg5 1Division of Digestive Diseases, Hepatology, and Nutrition, Connecticut Children’sMedicalCenter,Hartford, Connecticut; 2Division of Digestive Diseases, Hepatology, and Nutrition, Nationwide Children’s Hospital, Columbus, Ohio; 3Baylor College of Medicine, Children’s Nutrition Research Center, Texas Children’s Hospital, Houston, Texas; 4Department of Translational Science, Section of Pediatrics, University of Naples, Federico II, Naples, Italy; and 5Department of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Characterization of childhood and adolescent functional Rome III criteria emphasized that there should be “no evi- gastrointestinal disorders (FGIDs) has evolved during the 2- dence” for organic disease, which may have prompted a decade long Rome process now culminating in Rome IV. The focus on testing.1 In Rome IV, the phrase “no evidence of an era of diagnosing an FGID only when organic disease has inflammatory, anatomic, metabolic, or neoplastic process been excluded is waning, as we now have evidence to sup- that explain the subject’s symptoms” has been removed port symptom-based diagnosis. In child/adolescent Rome from diagnostic criteria. Instead, we include “after appro- IV, we extend this concept by removing the dictum that priate medical evaluation, the symptoms cannot be attrib- “ ” fi there was no evidence for organic disease in all de ni- uted to another medical condition.” This change permits “ tions and replacing it with after appropriate medical selective or no testing to support a positive diagnosis of an evaluation the symptoms cannot be attributed to another FGID.
    [Show full text]
  • Electrogastrography: Methodology, Validation and Applications
    J Neurogastroenterol Motil, Vol. 19 No. 1 January, 2013 pISSN: 2093-0879 eISSN: 2093-0887 http://dx.doi.org/10.5056/jnm.2013.19.1.5 Review JNM Journal of Neurogastroenterology and Motility Electrogastrography: Methodology, Validation and Applications Jieyun Yin* and Jiande D Z Chen Division of Gastroenterology, University of Texas Medical Branch, Galveston, Texas, USA; and Ningbo Pace Translational Medical Research Center, Beilun, Ningbo, China Electrogastrography (EGG) is a non-invasive method for the measurement of gastric myoelectrical activity. It was first dis- covered in 1921 and popularized in 1990s. EGG is attractive because it is non-invasive. However, due to its non-invasive na- ture, there have also been controversies regarding validity and applications of EGG. The aim of this review is to discuss the methodologies, validation and applications of EGG. Pros and cons of EGG will also be discussed in detail. First, the gastric slow wave and its correlation with gastric motility are presented. The association between gastric dysrhythmia and impaired gastric motility is reviewed. Secondly the method for recording the electrogastrogram is presented in detail and pitfalls in the recording and analysis of EGG are discussed. Thirdly, findings reported in the literature demonstrating the accuracy of EGG in recording gastric slow waves and gastric dysrhythmia are reviewed and discussed. The correlation of the electrogastrogram with gastric contraction is carefully discussed. Finally, applications of EGG in a few major areas are reviewed. (J Neurogastroenterol Motil 2013;19:5-17) Key Words Electrogastrography; Gastric slow waves; Gastrointestinal motility The EGG was first introduced in 1922 by Alvarez,1 redis- covered by Davis et al2 in 1957 and popularized in 1990s.3 Due to Introduction its non-invasive nature, EGG has received substantial attention Electrogastrography is a non-invasive technique for recording among researchers and clinicians and also the controversies and gastric myoelectrical activity using cutaneous electrodes placed concerns arosed.
    [Show full text]
  • 24-Hour Ambulatory Electrogastrography in Healthy Volunteers
    24-Hour Ambulatory Electrogastrography in Healthy Volunteers G. LINDBERG, M. IWARZON & B. HAMMARLLJND Karolinska Institutet, Section of Gastroenterology and Hepatology, Dept. of Medicine, Huddinge University Hospital, Huddinge, Sweden Lindberg G, Iwarzon M,Hammarlund B. 24-Hour ambulatory electrogastrography in healthy volunteers. Sand J Gastroenterol 1996;31:658-664. Background: Development of electrogastrography, the recording of gastric electric rhythm from cutaneous electrodes, for clinical purposes has been hampered by methodologic problems and the lack of an ambulatory technique. We have evaluated a newly developed system for ambulatory electro- gastrography. Methods: 24-Hour recordings were obtained from 30 healthy volunteers. We used digital filtering, a Hamming window, and spectral analysis to determine the dominant frequency of successive 256-sec segments of data. Results: Low-frequency noise disturbed the primary signal. After secondary filtering a stable normogastric (24cpm) rhythm was present during a median of 49% (range, 3679%)of the recording time. The mean frequency of gastric electric activity varied from 2.92 2 0.15 cprn (mean 2 SD) at mid-day to 2.72 2 0.13 cprn in the late night. Conclusions: Ambulatory recording of electrogastrography needs technical improvement. The electrogastrogram shows a circadian variation in frequency. Key words: Electrodes; electrodiagnosis; gastrointestinal motility, computer-assisted signal processing; human; reference values; stomach Greger Lindberg, M.D., Section of Gastroenterology and Hepatology, Dept. of Medicine, K63, Huddinge University Hospital, S-141 86 Huddinge, Sweden (fax: + 46 8 6082241) The recording of gastric electric activity from cutaneous arrive at a so-called running spectral analysis (10, 11). Thus, electrodes, so-called electrogastrography (EGG) was first EGG has shown disturbances of the gastric electric rhythm in described by Alvarez in 1922 (1).
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Clinical Utility of Electrogastrography and the Water Load Test in Patients with Upper Gastrointestinal Symptoms
    J. Smooth Muscle Res. (2006) 42 (5): 149–157 149 Original Clinical utility of electrogastrography and the water load test in patients with upper gastrointestinal symptoms Chien-Lin CHEN1, Chi-Tan HU1, Hsien-Hong LIN1 and Chih-Hsun YI1 1Department of Medicine, Buddhist Tzu Chi General Hospital and University School of Medicine, 707, Sec. 3, Chung-Yang Rd., Hualien 970, Taiwan Received July 31, 2006; Accepted September 14, 2006 Abstract We assessed gastric myoelectric functioning in patients with various gastrointestinal symptoms and to determine the utility of electrogastrography in differentiating specific disease entities. Electrogastrography with a water load was performed in 101 patients with reflux disease, 55 patients with active gastric ulcer, 59 patients with functional dyspepsia, and 30 controls. Upper gastrointestinal symptoms were assessed in each patient. Electrogastrography was abnormal in 41 (40.6%) patients with reflux disease, 31 (56.4%) patients with active gastric ulcer, and 26 (44.1%) patients with functional dyspepsia (P=NS). Water load tolerance was greater in controls than any patient group (all P<0.05). Symptoms predicted abnormal electrogastrography in reflux patents with satiety (OR=2.9; P<0.05) and in dyspeptic patients with nausea (OR=3.1; P<0.05). Although electrogastrography is helpful in differentiating subgroups of patients with nausea or satiety, it cannot directly differentiate disease states such as reflux disease, gastric ulcer, and functional dyspepsia. Key words: electrogastrography, gastric myoelectrical activity, gastrointestinal symptom Introduction Functional dyspepsia (FD) is common and is often defined as episodic or persistent upper abdominal symptoms related to eating (Barbara et al., 1989). Dyspeptic symptoms include vague epigastric or periumbilical discomfort, early satiety, postprandial fullness, bloating, regurgitation, nausea, and vomiting (Drossman, 1999).
    [Show full text]
  • Gastroparesis: 2014
    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
    [Show full text]
  • Gastroparesis and Dumping Syndrome: Current Concepts and Management
    Journal of Clinical Medicine Review Gastroparesis and Dumping Syndrome: Current Concepts and Management Stephan R. Vavricka 1,2,* and Thomas Greuter 2 1 Center of Gastroenterology and Hepatology, CH-8048 Zurich, Switzerland 2 Department of Gastroenterology and Hepatology, University Hospital Zurich, CH-8091 Zurich, Switzerland * Correspondence: [email protected] Received: 21 June 2019; Accepted: 23 July 2019; Published: 29 July 2019 Abstract: Gastroparesis and dumping syndrome both evolve from a disturbed gastric emptying mechanism. Although gastroparesis results from delayed gastric emptying and dumping syndrome from accelerated emptying of the stomach, the two entities share several similarities among which are an underestimated prevalence, considerable impairment of quality of life, the need for a multidisciplinary team setting, and a step-up treatment approach. In the following review, we will present an overview of the most important clinical aspects of gastroparesis and dumping syndrome including epidemiology, pathophysiology, presentation, and diagnostics. Finally, we highlight promising therapeutic options that might be available in the future. Keywords: gastroparesis; dumping syndrome; pathophysiology; clinical presentation; treatment 1. Introduction Gastroparesis and dumping syndrome both evolve from a disturbed gastric emptying mechanism. While gastroparesis results from significantly delayed gastric emptying, dumping syndrome is a consequence of increased flux of food into the small bowel [1,2]. The two entities share several important similarities: (i) gastroparesis and dumping syndrome are frequent, but also frequently overlooked; (ii) they affect patient’s quality of life considerably due to possibly debilitating symptoms; (iii) patients should be taken care of within a multidisciplinary team setting; and (iv) treatment should follow a step-up approach from dietary modifications and patient education to pharmacological interventions and, finally, surgical procedures and/or enteral feeding.
    [Show full text]
  • Myoelectric Activity of the Stomach Gastroelectromyography and Electrogastrography
    MYOELECTRIC ACTIVITY OF THE STOMACH GASTROELECTROMYOGRAPHY AND ELECTROGASTROGRAPHY PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE GENEESKUNDE AAN DE ERASMUS UNIVERSITEIT ROTTERDAM OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. J. SPERNA WEILAND EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN DE OPENBARE VERDEDIGING ZAL PLAATS VINDEN OP WOENSDAG 4 JUNI 1980 DES NAMIDDAGS TE 4.15 UUR DOOR ANDREAS JOHANNES PETRUS MARIA SMOUT GEBOREN TE AMSTERDAM DELFT UNIVERSITY PRESS I 1980 PROMOTOREN . : PROF. DR. G. VAN DEN BRINK PROF. DR. D.L WESTBROEK CO-REFERENTEN: PROF. DR. J.TH.F. BOELES PROF. DR. M. FRENKEL aan Anja en Danielle VOORWOORO Aan het tot stand komen van dit proefschrift hebben zeer velen in belangrijke mate bijgedragen. Allen ben ik zeer erkentel ijk. In het bijzonder wil ik alle (vaste en tijdel ijke) medewerkers van de afdel ing Medische Technologie der Erasmus Universiteit danken voor de uitermate plezie­ rige en vruchtbare samenwerking. VI CONTENTS page 1. INTRODUCTION AND OBJECTIVES OF THE STUDIES 2. ANATOMY OF THE STOMACH 3 2.1 Macroscopic anatomy 3 2.2 Microscopic anatomy of intercellular contacts between gastric smooth muscle cells 5 3. INTRACELLULAR ELECTRICAL ACTIVITY OF GASTRIC SMOOTH MUSCLE (LITERATURE SURVEY) 9 3.1 Introduction 9 3.2 Frequencies of action potentials in gastric muscle strips 10 3.3 Configurations of action potentials of gastric muscle 10 3. 3.1 Resting membrane potential 11 3.3.2 Depolarization phase 11 3.3.3 Plateau phase 12 3.3.4 Repolarization phase 15 3.4 Intracellular electrical activity of fundic smooth muscle cells 15 4.
    [Show full text]
  • Chapter 26: Paediatric Gastroenterology
    A National Model of Care for Paediatric Healthcare Services in Ireland Chapter 26: Paediatric Gastroenterology Clinical Strategy and Programmes Division National Clinical Programme for Paediatrics and Neonatology: A National Model of Care for Paediatric Healthcare Services in Ireland TABLE OF CONTENTS 26.0 Introduction 2 26.1 Current Service Provision 4 26.2 Proposed Model of Care 8 26.3 Requirements for Successful Implementation of Model of Care 11 26.4 Governance 13 26.5 Programme Metrics and Evaluation 14 26.6 Key Recommendations 15 26.7 Abbreviations and Acronyms 15 26.8 References 16 1 National Clinical Programme for Paediatrics and Neonatology: A National Model of Care for Paediatric Healthcare Services in Ireland 26.0 INTRODUCTION Paediatric gastroenterology encompasses the management of disorders of the intestine, liver and pancreas, and conditions leading to intestinal failure/severe nutritional compromise. Tertiary paediatric gastroenterology, hepatology and nutrition services for Ireland are provided in one centre, Our Lady’s Children’s Hospital, Crumlin (Crumlin), and will move to the new children’s hospital when it is built. This is in line with international recommendations that specialised services should be delivered in tertiary care centres of excellence. The diagnosis and management of the following tertiary conditions are included among the national paediatric gastroenterology services: • Inflammatory bowel disease (IBD) – medical and surgical care provided centrally, with shared care provided locally by general practitioners
    [Show full text]